UK approves Pfizer-BioNTech COVID-19 vaccine for children of age group 12 to 15

Pfizer-BioNTech vaccine may require third dose, companies seek approval

The UK on Friday approved the COVID-19 vaccine developed by Pfizer and BioNTech for children of age group 12 to 15, following similar clearances in the United States and the EU.

The UK regulator said that it would now be up to the UK’s Joint Committee on Vaccination and Immunisation (JCVI) to decide whether to go ahead and vaccinate this age group as part of Britain’s vaccination plan.

Also Read | Myths and Facts of COVID-19 vaccination in India; here is what PM Modi govt doing to vaccinate Indians

UK approved COVID-19 vaccine developed by Pfizer and BioNTech for children of age group 12 to 15, after clearances in US and the EU.

The children aged 12-15 are already being inculcated with the Pfizer vaccine in the US, while France and Germany are mulling to start offering the shot to that age group in June.

Also Read | Coronavirus India: Third wave of coronavirus in Maharashtra? Over 8,000 children test positive in 1 district

UK approved COVID-19 vaccine developed by Pfizer and BioNTech for children of age group 12 to 15, after clearances in US and the EU.

Meanwhile, Britain’s Health and Social Care department said that it would provide an update after JCVI would make its decision.

On the other hand, the chief executive of the UK Medicines and Healthcare products Regulatory Agency June Raine said that her agency had reviewed the clinical trial data in children of ages 12 to 15.

UK approved COVID-19 vaccine developed by Pfizer and BioNTech for children of age group 12 to 15, after clearances in US and the EU.

Raine further said the Pfizer and BioNTech COVID-19 vaccine is safe and effective in children of this age group.

Likewise, the World Health Organisation (WHO) has urged rich countries to give shots to the COVAX scheme instead.

Click here to follow PTC News on Twitter

-PTC News